Protalix BioTherapeutics, Inc.
General ticker "PLX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $175.7M (TTM average)
Protalix BioTherapeutics, Inc. follows the US Stock Market performance with the rate: 24.6%.
Estimated limits based on current volatility of 2.3%: low 2.63$, high 2.76$
Factors to consider:
- Total employees count: 226 (+6.1%) as of 2025
- Top business risk factors: Operational and conduct risks, Safety incidents, Limited operating history, Manufacturing issues, Regulatory and compliance
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.71$, 3.27$]
- 2026-12-31 to 2027-12-31 estimated range: [1.90$, 3.54$]
Financial Metrics affecting the PLX estimates:
- Positive: with PPE of -20.2 at the end of fiscal year the price was low
- Negative: negative Operating cash flow
- Positive: -13.52 < Operating profit margin, % of -9.44
- Positive: 58.56 < Shareholder equity ratio, % of 58.57 <= 69.38
- Positive: -7.72 < Return on assets ratio (scaled to [-100,100]) of -7.42
Short-term PLX quotes
Long-term PLX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $65.49MM | $53.40MM | $52.74MM |
| Operating Expenses | $55.03MM | $49.48MM | $58.24MM |
| Operating Income | $10.46MM | $3.92MM | $-5.50MM |
| Non-Operating Income | $-1.89MM | $0.24MM | $-0.11MM |
| R&D Expense | $17.09MM | $12.97MM | $19.57MM |
| Income(Loss) | $8.57MM | $4.15MM | $-5.61MM |
| Taxes | $0.25MM | $1.22MM | $1.00MM |
| Net Income(Loss)* | $8.31MM | $2.93MM | $-6.60MM |
| Stockholders Equity | $33.57MM | $43.21MM | $48.23MM |
| Inventory | $19.05MM | $21.24MM | $25.73MM |
| Assets | $84.43MM | $73.42MM | $82.35MM |
| Operating Cash Flow | $-1.32MM | $8.67MM | $-11.99MM |
| Capital expenditure | $1.15MM | $1.28MM | $1.64MM |
| Investing Cash Flow | $-16.71MM | $4.22MM | $-2.37MM |
| Financing Cash Flow | $24.67MM | $-16.79MM | $9.33MM |
| Earnings Per Share** | $0.12 | $0.04 | $-0.08 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.